Stock 600196 SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Equities

600196

CNE000000X38

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-04-29 EDT 		5-day change 1st Jan Change
23.67 CNY -0.17% Intraday chart for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. +4.09% -5.43%
04-30 Fosun Pharma's Q1 Profit Slumps 38% MT
04-29 Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 65,086 125,791 113,862 86,922 61,592 56,484 - -
Enterprise Value (EV) 1 77,050 139,217 127,150 100,183 80,958 71,949 74,208 71,101
P/E ratio 20.5 x 37.8 x 26.5 x 24.6 x 28.1 x 17.1 x 14.7 x 13.8 x
Yield 1.47% 0.8% 1.14% 1.19% 1.08% 1.77% 2.07% 2.56%
Capitalization / Revenue 2.28 x 4.15 x 2.92 x 1.98 x 1.49 x 1.32 x 1.16 x 1.05 x
EV / Revenue 2.7 x 4.59 x 3.26 x 2.28 x 1.96 x 1.68 x 1.52 x 1.33 x
EV / EBITDA 13.1 x 22.2 x 15.7 x 14.5 x 13.1 x 10.3 x 8.87 x 9.03 x
EV / FCF -109 x -75 x -137 x -64.1 x -42.3 x 15.5 x 48.3 x 42.8 x
FCF Yield -0.92% -1.33% -0.73% -1.56% -2.36% 6.46% 2.07% 2.34%
Price to Book 2.14 x 3.74 x 3.21 x 2.11 x 1.46 x 1.31 x 1.18 x 1.16 x
Nbr of stocks (in thousands) 2,562,899 2,562,899 2,562,899 2,672,157 2,672,399 2,672,399 - -
Reference price 2 26.60 53.99 48.94 35.24 25.03 23.67 23.67 23.67
Announcement Date 20-03-30 21-03-29 22-03-22 23-03-27 24-03-26 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 28,585 30,307 39,005 43,952 41,400 42,863 48,830 53,585
EBITDA 1 5,874 6,282 8,105 6,889 6,160 7,009 8,370 7,871
EBIT 1 4,494 4,721 6,314 4,657 3,308 2,163 2,699 3,370
Operating Margin 15.72% 15.58% 16.19% 10.59% 7.99% 5.05% 5.53% 6.29%
Earnings before Tax (EBT) 1 4,526 4,678 6,054 4,574 3,265 4,920 5,635 6,304
Net income 1 3,322 3,663 4,735 3,731 2,386 3,570 4,090 4,438
Net margin 11.62% 12.09% 12.14% 8.49% 5.76% 8.33% 8.38% 8.28%
EPS 2 1.300 1.430 1.850 1.430 0.8900 1.385 1.609 1.712
Free Cash Flow 1 -705.7 -1,857 -926.7 -1,564 -1,913 4,645 1,537 1,662
FCF margin -2.47% -6.13% -2.38% -3.56% -4.62% 10.84% 3.15% 3.1%
FCF Conversion (EBITDA) - - - - - 66.27% 18.37% 21.11%
FCF Conversion (Net income) - - - - - 130.14% 37.58% 37.45%
Dividend per Share 2 0.3900 0.4300 0.5600 0.4200 0.2700 0.4183 0.4897 0.6059
Announcement Date 20-03-30 21-03-29 22-03-22 23-03-27 24-03-26 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 11,957 10,382 10,893 10,270 12,341 10,871 10,445 9,305 10,699 10,157 10,889 10,631 11,279 10,475
EBITDA - - - - - - - - - - - - - -
EBIT 1 1,615 863.1 1,136 1,046 1,064 1,427 1,255 659.6 -34.69 1,021 363.7 867.5 456 706.2
Operating Margin 13.5% 8.31% 10.43% 10.18% 8.62% 13.13% 12.02% 7.09% -0.32% 10.06% 3.34% 8.16% 4.04% 6.74%
Earnings before Tax (EBT) - - - - - - - - - - - - - -
Net income - - - - - - - - - - - - - -
Net margin - - - - - - - - - - - - - -
EPS 2 0.4600 0.1800 0.4200 0.3500 0.4800 0.3700 0.3000 0.1900 0.0400 0.2300 0.3400 0.4400 0.3200 0.2800
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 22-03-22 22-04-26 22-08-29 22-10-30 23-03-27 23-04-28 23-08-29 23-10-30 24-03-26 24-04-29 - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 11,964 13,426 13,289 13,261 19,366 15,465 17,724 14,617
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.037 x 2.137 x 1.639 x 1.925 x 3.144 x 2.206 x 2.118 x 1.857 x
Free Cash Flow 1 -706 -1,857 -927 -1,564 -1,913 4,645 1,537 1,662
ROE (net income / shareholders' equity) 11.6% 10.8% 12.4% 9.04% 5.29% 6.76% 8.25% 8.78%
ROA (Net income/ Total Assets) 4.53% 4.58% 5.35% 3.73% 2.18% 2.53% 2.9% 3.3%
Assets 1 73,341 79,904 88,433 100,022 109,663 141,087 141,210 134,449
Book Value Per Share 2 12.40 14.40 15.30 16.70 17.10 18.00 20.00 20.50
Cash Flow per Share 2 1.260 1.010 1.540 1.580 1.280 2.270 1.760 2.000
Capex 1 3,928 4,437 4,875 5,782 5,328 4,900 3,919 4,577
Capex / Sales 13.74% 14.64% 12.5% 13.15% 12.87% 11.43% 8.03% 8.54%
Announcement Date 20-03-30 21-03-29 22-03-22 23-03-27 24-03-26 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
23.67 CNY
Average target price
29.44 CNY
Spread / Average Target
+24.38%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. Stock Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
-5.43% 7.8B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.25% 704B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+28.59% 577B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.55% 348B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.16% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.36% 288B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.81% 234B
NOVARTIS AG Stock Novartis AG
+4.93% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
AMGEN INC. Stock Amgen Inc.
-3.69% 147B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600196 Stock
  4. Financials Shanghai Fosun Pharmaceutical (Group) Co., Ltd.